Legal and financial questions of Pfizer-Novo-Metsera
Shareholder Primacy
00:00
Why Antitrust Risk Made Novo's Bid Risky
Mike and Ann explain antitrust concerns, HSR preclearance, and why Novo's ownership of weight-loss drugs heightens regulatory risk.
Play episode from 08:23
Transcript
